Isotopes

Theragnostics Strengthens Board of Directors with Key Appointments

Retrieved on: 
Wednesday, August 4, 2021
Medicine, Physical sciences, Health sciences, Medical physics, Medicinal radiochemistry, Radiation therapy, Isotopes, Molecular imaging, Radiopharmaceutical, Radionuclide therapy

LONDON, Aug. 4, 2021 /PRNewswire/ -- Theragnostics, which is developing molecular radiotherapy for imaging and treating a broad range of cancers, announces today the appointments of Dr Dennis Langer and Professor Ken Herrmann as Non-Executive Directors to its Board.

Key Points: 
  • LONDON, Aug. 4, 2021 /PRNewswire/ -- Theragnostics, which is developing molecular radiotherapy for imaging and treating a broad range of cancers, announces today the appointments of Dr Dennis Langer and Professor Ken Herrmann as Non-Executive Directors to its Board.
  • Ian Gowrie-Smith, Executive Chairman of Theragnostics, said:"We are very pleased to welcome two high calibre board members to Theragnostics.
  • Ken's extensive knowledge in the clinical development and commercialisation of radiopharmaceuticals is key to the advancement and maturity of Theragnostics.
  • Greg Mullen, Chief Executive Officer of Theragnostics, added:"I am very pleased to have Dennis and Ken with their expertise and track record, join our board.

Theragnostics Strengthens Board of Directors with Key Appointments

Retrieved on: 
Wednesday, August 4, 2021
Medicine, Physical sciences, Health sciences, Medical physics, Medicinal radiochemistry, Radiation therapy, Isotopes, Molecular imaging, Radiopharmaceutical, Radionuclide therapy

LONDON, Aug. 4, 2021 /PRNewswire/ -- Theragnostics, which is developing molecular radiotherapy for imaging and treating a broad range of cancers, announces today the appointments of Dr Dennis Langer and Professor Ken Herrmann as Non-Executive Directors to its Board.

Key Points: 
  • LONDON, Aug. 4, 2021 /PRNewswire/ -- Theragnostics, which is developing molecular radiotherapy for imaging and treating a broad range of cancers, announces today the appointments of Dr Dennis Langer and Professor Ken Herrmann as Non-Executive Directors to its Board.
  • Ian Gowrie-Smith, Executive Chairman of Theragnostics, said:"We are very pleased to welcome two high calibre board members to Theragnostics.
  • Ken's extensive knowledge in the clinical development and commercialisation of radiopharmaceuticals is key to the advancement and maturity of Theragnostics.
  • Greg Mullen, Chief Executive Officer of Theragnostics, added:"I am very pleased to have Dennis and Ken with their expertise and track record, join our board.

Council on Radionuclides and Radiopharmaceuticals, Inc. Supports the Facilitating Innovative Nuclear Diagnostics (FIND) Act of 2021

Retrieved on: 
Tuesday, July 27, 2021
Surgery, Medical devices, Public policy, Government, Healthcare reform, Biotechnology, Other Health, Radiology, Health, Oncology, Physical sciences, Natural sciences, Medicinal radiochemistry, Chemistry, Isotopes, Radiopharmaceuticals, Medicinal chemistry, Nuclear medicine, Radiology, Medicare, Radionuclide, Medicine

The Council on Radionuclides and Radiopharmaceuticals, Inc. (CORAR), along with physicians and patient organizations, supports the introduction of H.R.

Key Points: 
  • The Council on Radionuclides and Radiopharmaceuticals, Inc. (CORAR), along with physicians and patient organizations, supports the introduction of H.R.
  • 4479, the Facilitating Innovative Nuclear Diagnostics (FIND) Act of 2021 by Congressmen Scott Peters (D-CA), Bobby Rush (D-IL), Neal Dunn (R-FL) and Greg Murphy (R-NC).
  • The FIND Act will ensure that patients have access to precision diagnostic radiopharmaceutical (RP) drugs and promotes continued life-saving innovations in nuclear medicine.
  • The current Medicare reimbursement structure in the outpatient setting packages diagnostic RP drugs into nuclear medicine procedure payments.

Plus Therapeutics Reports Second Quarter 2021 Financial Results and Business Highlights

Retrieved on: 
Thursday, July 22, 2021
Physical sciences, Natural sciences, Physics, Isotopes, Nuclear chemistry, Radioactivity, Radionuclide, Plus Therapeutics

); Conference ID: PSTVQ221

Key Points: 
  • ); Conference ID: PSTVQ221
    The webcast can be accessed live via the investor section of the Plus Therapeutics website at ir.plustherapeutics.com/events and will be available for replay beginning two hours after the conclusion of the conference call.
  • Plus Therapeutics is a clinical-stage pharmaceutical company whose radiotherapeutic portfolio is concentrated on nanoliposome-encapsulated radionuclides for several cancer targets.
  • Central to the Companys drug development is a unique nanotechnology platform designed to reformulate, deliver and commercialize multiple drugs targeting rare cancers and other diseases.
  • There may be events in the future that the Company is unable to predict, or over which it has no control, and its business, financial condition, results of operations and prospects may change in the future.

Picarro Releases New High-Throughput Modes for the L2130-i Isotopic Water Analyzer

Retrieved on: 
Tuesday, May 4, 2021
Physical sciences, Isotopes, Natural sciences, Chemistry, Stable isotope ratio

b'SANTA CLARA, Calif., May 4, 2021 /PRNewswire/ -- Picarro Inc. , a leading provider of gas concentration and stable isotope analyzers and systems for science and industrial applications, today released the Express and Survey Modes for the L2130-i Isotopic Water Analyzer .

Key Points: 
  • b'SANTA CLARA, Calif., May 4, 2021 /PRNewswire/ -- Picarro Inc. , a leading provider of gas concentration and stable isotope analyzers and systems for science and industrial applications, today released the Express and Survey Modes for the L2130-i Isotopic Water Analyzer .
  • The new measurement modes enable the L2130-i to deliver the fastest, most precise water isotope measurements of 18O and D. These measurements are critical for advanced research into all aspects of the water cyclewater vapor, liquid water or water trapped in solidsand for demanding applications such as paleoclimatology and oceanography.\nThe L2130-i now has three modes.
  • Combining the Express and Survey modes will further increase throughput by reducing the time it takes to measure 100 samples by up to 68 hours.
  • With the addition of these new modes the Picarro L2130-i is now the fastest, most precise laser-based isotopic water analyzer.\n"Depending on the number of samples being tested, isotopic water analysis can take days," said Joel Avrunin, Vice President of Scientific Instrumentation for Picarro.

Stable Isotope Labeled Compounds Market Research and Outlook Report - Global Trends, Growth Opportunities and Forecasts to 2028 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 10, 2021
Chemicals, Plastics, Manufacturing, Physical sciences, Natural sciences, Chemistry, Isotopes, Biochemistry methods, Stable isotope ratio, Lithium

The "Stable Isotope Labeled Compounds Market Research and Outlook, 2020 - Trends, Growth Opportunities and Forecasts to 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Stable Isotope Labeled Compounds Market Research and Outlook, 2020 - Trends, Growth Opportunities and Forecasts to 2028" report has been added to ResearchAndMarkets.com's offering.
  • Stable Isotope Labeled Compounds market size outlook report provides comprehensive coverage of market landscape including strategic growth areas, unique insights, and major trends across Stable Isotope Labeled Compounds market types and applications.
  • It is a focused study on Stable Isotope Labeled Compounds market space including global and regional eight-year forecasts for revenues as well as proffers detailed snapshots of country-wide Stable Isotope Labeled Compounds market revenues.
  • The Stable Isotope Labeled Compounds market report presents key trends and dynamics making an impact on the Stable Isotope Labeled Compounds companies across the Americas, Europe, Asia Pacific, and Other markets and provides innovative approaches to stay ahead of the competition in the opportunity-rich Stable Isotope Labeled Compounds market.

Global $9.9 Billion Radiopharmaceuticals Market to 2027 - Intra-operative Lymphatic Mapping (ILM) Creates New Opportunities

Retrieved on: 
Tuesday, January 12, 2021
Health sciences, Medicine, Health, Occupational safety and health, Medicinal radiochemistry, Radiopharmaceuticals, Medicinal chemistry, Isotopes, COVID-19 pandemic, Coronavirus disease

DUBLIN, Jan. 12, 2021 /PRNewswire/ -- The "Radiopharmaceuticals - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Jan. 12, 2021 /PRNewswire/ -- The "Radiopharmaceuticals - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • The global market for Radiopharmaceuticals is expected to slump by -6.3% in the year 2020 and thereafter recover to reach US$9.9 billion by the year 2027, trailing a post COVID-19 CAGR of 9.4% over the analysis period 2020 through 2027.
  • Amid the COVID-19 outbreak, most companies have reported some form of disruption in their supply chains owing to transportation restrictions.
  • The crisis has also resulted in supply issues associated with radiopharmaceuticals, radioisotopes and kits for therapeutic and diagnostic applications.

Global Radiopharmaceuticals Market Report 2020-2027 - ResearchAndMarkets.com

Retrieved on: 
Monday, January 11, 2021
Radiology, Pharmaceutical, Health, Health sciences, Medicine, Medicinal radiochemistry, Health, Radiopharmaceuticals, Medicinal chemistry, Radiology, Isotopes, Nuclear medicine, COVID-19 pandemic

The "Radiopharmaceuticals - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Radiopharmaceuticals - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • The global market for Radiopharmaceuticals is expected to slump by -6.3% in the year 2020 and thereafter recover to reach US$9.9 billion by the year 2027, trailing a post COVID-19 CAGR of 9.4% over the analysis period 2020 through 2027.
  • The crisis has also resulted in supply issues associated with radiopharmaceuticals, radioisotopes and kits for therapeutic and diagnostic applications.
  • The COVID-19 outbreak has complicated the scenario owing to ongoing restrictions on flights that have severely disrupted global supply chains, prompting participants to ensure reliable radiopharmaceuticals supply for nuclear medicine.

U.S. Deputy Secretary of Energy Mark W. Menezes Visits NorthStar Medical Radioisotopes

Retrieved on: 
Thursday, September 17, 2020
Medical devices, Health, Radiology, Pharmaceutical, Cardiology, Biotechnology, Physical sciences, Natural sciences, Nuclear physics, Radioactivity, Radiopharmaceuticals, Medicinal radiochemistry, Radiobiology, Isotopes, Radiopharmacology, Radionuclide, Northstar, Isotopes of molybdenum

NorthStar Medical Radioisotopes , LLC, a global innovator in the production and distribution of radioisotopes used for medical imaging, today announced that Deputy Secretary of Energy Mark W. Menezes visited the Companys Beloit, Wis. headquarters on September 11, 2020.

Key Points: 
  • NorthStar Medical Radioisotopes , LLC, a global innovator in the production and distribution of radioisotopes used for medical imaging, today announced that Deputy Secretary of Energy Mark W. Menezes visited the Companys Beloit, Wis. headquarters on September 11, 2020.
  • During the trip, the Deputy Secretary toured two companies that are committed to or actively producing the important medical radioisotope molybdenum-99 (Mo-99).
  • We were honored to welcome Deputy Secretary Menezes and the DOE to visit NorthStar Medical Radioisotopes, said Steve Merrick, President and CEO of NorthStar Medical Radioisotopes.
  • Founded in 2006 and based in Beloit, Wis., NorthStar Medical Radioisotopes, LLC is a wholly-owned subsidiary of NorthStar Medical Technologies, LLC.

Isotopia Molecular Imaging and CPDC Announce Production Agreement for n.c.a. Lu-177

Retrieved on: 
Tuesday, September 8, 2020
Physical sciences, Chemistry, Natural sciences, Medicinal radiochemistry, Radiopharmaceuticals, Medicinal chemistry, Isotopes, Molecular imaging, Lutetium, Petach, Imaging

PETACH TIKVA, Israel, Sept. 8, 2020 /PRNewswire/ -- Isotopia Molecular Imaging and CPDC are pleased to announce that they have entered into an agreement for the production and distribution of no-carrier-added Lutetium-177(n.c.a.

Key Points: 
  • PETACH TIKVA, Israel, Sept. 8, 2020 /PRNewswire/ -- Isotopia Molecular Imaging and CPDC are pleased to announce that they have entered into an agreement for the production and distribution of no-carrier-added Lutetium-177(n.c.a.
  • The Centre for Probe Development and Commercialization (CPDC), a global leader in the development, production and commercialization of radiopharmaceuticals, will produce n.c.a.
  • Isotopia Molecular Imaging Ltd. is a collaboration between The Metrontario Group and Israel's leading scientists in the field of radiopharmaceuticals.
  • Isotopia creates collaborations between the scientific and medical community to further develop and experiment with new markers for imaging applications and molecular therapy.